君行健资本落地两支基金

Core Viewpoint - Junxingjian Capital has accelerated its investment strategy in the biomedical and advanced manufacturing sectors by successfully registering two new funds, expanding its fund matrix to eight [1][2] Group 1: Fund Overview - Junxingjian Capital's new funds include Qingdao Junxingjian Tai Fund, focusing on biomedical fields such as biomedicine, medical devices, and pharmaceutical R&D services [1] - The other fund, Zhaiguang Zhiyuan Fund, targets advanced manufacturing sectors including new materials, high-end equipment, and military technology [1] Group 2: Strategic Focus - The funds aim to discover value in innovative diagnostic technologies and high-end medical devices, particularly targeting companies with core technological barriers that are in critical clinical stages or early commercialization [1] - The advanced manufacturing fund emphasizes investment in innovative companies that enhance supply chain security and achieve import substitution, covering the entire innovation chain from basic materials to end equipment [1] Group 3: Company Growth and Ecosystem - Since its establishment in 2021, Junxingjian Capital has developed a full-cycle service system with over 600 million yuan in managed funds, investing in more than 20 quality enterprises, many of which are entering critical capitalization stages [2] - The dual fund registration reflects an upgrade in the strategic layout for hard technology and health sectors, leveraging the ecosystem of invested enterprises to connect them with supply chains, customers, and capital markets [2]